Share-based Payment Arrangement, Expense of Dyne Therapeutics, Inc. from 30 Sep 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Dyne Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2019 to 31 Dec 2025.
  • Dyne Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $11,226,000, a 7.1% increase year-over-year.
  • Dyne Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $45,851,000, a 0.03% decline year-over-year.
  • Dyne Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2025 was $45,851,000, a 0.03% decline from 2024.
  • Dyne Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $45,864,000, a 130% increase from 2023.
  • Dyne Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $19,972,000, a 32% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Dyne Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $45,851,000 $11,226,000 +$749,000 +7.1% 01 Oct 2025 31 Dec 2025 10-K 02 Mar 2026 2025 FY
Q3 2025 $45,102,000 $11,082,000 +$2,337,000 +27% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $42,765,000 $10,523,000 +$3,787,000 +56% 01 Apr 2025 30 Jun 2025 10-Q 28 Jul 2025 2025 Q2
Q1 2025 $38,978,000 $13,020,000 -$6,886,000 -35% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $45,864,000 $10,477,000 +$4,746,000 +83% 01 Oct 2024 31 Dec 2024 10-K 02 Mar 2026 2025 FY
Q3 2024 $41,118,000 $8,745,000 +$3,870,000 +79% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $37,248,000 $6,736,000 +$1,987,000 +42% 01 Apr 2024 30 Jun 2024 10-Q 28 Jul 2025 2025 Q2
Q1 2024 $35,261,000 $19,906,000 +$15,289,000 +331% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $19,972,000 $5,731,000 +$1,899,000 +50% 01 Oct 2023 31 Dec 2023 10-K 02 Mar 2026 2025 FY
Q3 2023 $18,073,000 $4,875,000 +$1,048,000 +27% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $17,025,000 $4,749,000 +$1,718,000 +57% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $15,307,000 $4,617,000 +$129,000 +2.9% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $15,178,000 $3,832,000 -$2,181,000 -36% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $17,359,000 $3,827,000 +$189,000 +5.2% 01 Jul 2022 30 Sep 2022 10-Q 30 Oct 2023 2023 Q3
Q2 2022 $17,170,000 $3,031,000 -$1,208,000 -28% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $18,378,000 $4,488,000 +$836,000 +23% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $17,542,000 $6,013,000 +$1,798,000 +43% 01 Oct 2021 31 Dec 2021 10-K 02 Mar 2023 2022 FY
Q3 2021 $15,744,000 $3,638,000 +$1,403,000 +63% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $14,341,000 $4,239,000 +$4,164,000 +5552% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $10,177,000 $3,652,000 +$3,586,000 +5433% 01 Jan 2021 31 Mar 2021 10-Q 02 May 2022 2022 Q1
Q4 2020 $6,591,000 $4,215,000 01 Oct 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
Q3 2020 $2,235,000 +$2,228,000 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $75,000 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $66,000 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q3 2019 $7,000* 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3

Dyne Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $45,851,000 -$13,000 -0.03% 01 Jan 2025 31 Dec 2025 10-K 02 Mar 2026 2025 FY
2024 $45,864,000 +$25,892,000 +130% 01 Jan 2024 31 Dec 2024 10-K 02 Mar 2026 2025 FY
2023 $19,972,000 +$4,794,000 +32% 01 Jan 2023 31 Dec 2023 10-K 02 Mar 2026 2025 FY
2022 $15,178,000 -$2,364,000 -13% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $17,542,000 +$10,951,000 +166% 01 Jan 2021 31 Dec 2021 10-K 02 Mar 2023 2022 FY
2020 $6,591,000 +$6,565,000 +25250% 01 Jan 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
2019 $26,000 01 Jan 2019 31 Dec 2019 10-K 04 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.